Brazilian Journal of Anesthesiology
https://app.periodikos.com.br/journal/rba/article/doi/10.1590/S0034-70942003000600009
Brazilian Journal of Anesthesiology
Scientific Article

Efeitos cardiovasculares de duas doses de dexmedetomidina: estudo experimental em cães

Cardiovascular effects of two dexmedetomidine doses: experimental study in dogs

Nivaldo Ribeiro Villela; Paulo do Nascimento Júnior; Lídia Raquel de Carvalho

http://dx.doi.org/10.1590/S0034-70942003000600009 Braz J Anesthesiol, vol.53, n6, p.784-796, 2003
PDF
Downloads: 0
Views: 1026

Resumo

JUSTIFICATIVA E OBJETIVOS: A dexmedetomidina é um novo agonista alfa2-adrenérgico, havendo, atualmente, crescente interesse no seu uso em Anestesiologia, por reduzir o consumo de anestésicos e promover estabilidade hemodinâmica. O objetivo desta pesquisa foi estudar os efeitos cardiovasculares da dexmedetomidina no cão anestesiado, empregando-se duas doses distintas e semelhantes àquelas utilizadas em Anestesiologia. MÉTODO: 36 cães adultos anestesiados com propofol, fentanil e isoflurano foram divididos em três grupos: G1, injeção de 20 ml de solução de cloreto de sódio a 0,9%, em 10 minutos, seguida de injeção de 20 ml da mesma solução, em 1 hora; G2, injeção de 20 ml de solução de cloreto de sódio a 0,9% contendo dexmedetomidina (1 µg.kg-1), em 10 minutos, seguida de injeção de 20 ml da mesma solução, em 1 hora e G3, injeção de 20 ml de solução de cloreto de sódio a 0,9% contendo dexmedetomidina (2 µg.kg-1) em 10 minutos, seguida de injeção de 20 ml da mesma solução, em 1 hora. Estudaram-se os atributos cardiovasculares em quatro momentos: M1, controle; M2, após a injeção inicial de 20 ml da solução em estudo, em 10 minutos, coincidindo com o início da injeção da mesma solução, em 1 hora; M3, 60 minutos após M2 e M4, 60 minutos após M3. RESULTADOS: A freqüência cardíaca (FC) diminuiu no G2, no M2, retornando aos valores basais no M3, enquanto no G3 diminuiu no M2, mantendo-se baixa durante todo o experimento. No G1 houve aumento progressivo da FC. Em nenhum grupo houve alteração da pressão arterial. A resistência vascular sistêmica (RVS) manteve-se estável no G2 e G3, enquanto no G1 apresentou redução em M2, mantendo-se baixa ao longo do experimento. O índice cardíaco (IC) não apresentou alterações significativas no G2 e G3, mas aumentou progressivamente no G1. CONCLUSÕES: Conclui-se que no cão, nas condições experimentais empregadas, a dexmedetomidina diminui a FC de forma dose-dependente, inibe a redução da RVS produzida pelo isoflurano e impede a ocorrência de resposta hiperdinâmica durante o experimento.

Palavras-chave

ANIMAL, DROGAS, DROGAS

Abstract

BACKGROUND AND OBJECTIVES: There has been a growing interest in the anesthetic use of dexmedetomidine, a new alpha2-adrenergic agonist, due to decreased anesthetics consumption and better cardiovascular stability that it promoter. This study aimed at investigating cardiovascular effects of two different dexmedetomidine doses in anesthetized dogs. METHODS: The study involved 36 adult dogs anesthetized with propofol, fentanyl and isoflurane distributed in three groups which received: G1, 20 ml saline injection in 10 minutes, followed by 20 ml of the same solution infused in one hour; G2, 20 ml dexmedetomidine-containing saline (1 µg.kg-1) in 10 minutes, followed by 20 ml of the same solution infused one hour; and G3, of dexmedetomidine-containing saline (2 µg.kg-1) in 10 minutes, followed by 20 ml of the same solution infused in one hour. Cardiovascular attributes were evaluated in four moments: M1, control, M2, after initial 20 ml injection of the studied solution, coincident with the beginning of the same solution injection in one hour; M3, 60 minutes after M2 and M4, 60 minutes after M3. RESULTS: G2 heart hate (HR) was decreased at M2, returning to baseline values at M3, while in G3 it was decreased at M2 but was kept so throughout the experiment. There has been progressive HR increase in G1. There were no significant changes in mean blood pressure in all group. Systemic vascular resistance (SVR) was maintained stable in G2 and G3, but was decreased in G1 at M3. Cardiac index (CI) was not significantly changed in G2 and G3, but has progressively increased in G1. CONCLUSIONS: In dogs under these experimental conditions, dexmedetomidine has induced a dose-dependent HR decrease, has inhibited isoflurane-induced SVR decrease and has prevented hyperdynamic responses throughout the experiment.

Keywords

ANIMAL, DRUGS, DRUGS

References

Udelsman R, Norton JA, Jelenich SE. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol. 1987;64:986-994.

Oliver MF, Goldman L, Julian DG. Effects of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European mivazerol trial (RMIT). Anesthesiology. 1999;91:951-961.

Hayashi Y, Maze M. Alpha2 adrenoceptor agonists and anaesthesia. Br J Anaesth. 1993;71:108-118.

Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans. Baillière’s Clin Anesthesiol. 2000;14:261-269.

Doze VA, Chen BX, Maze M. Dexmedetomidine produces a hypnotic-anesthetic action an rats via activation of alpha2-adrenoceptors. Anesthesiology. 1989;71:75-79.

Nguyen D, Abdul-Rasool I, Ward D. Ventilatory effects of dexmedetomidine, atipamezole, and isoflurane in dogs. Anesthesiology. 1992;76:573-579.

Scheinin M, Kallio A, Koulu M. Sedative and cardiovascular effects of medetomidine, a novel selective alpha2 adrenoceptor agonist, in healthy volunteers. Br J Clin Pharmacol. 1987;4:443-451.

Kallio A, Scheinin M, Koulu M. Effects of dexmedetomidine, a selective alpha2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther. 1989;46:33-42.

Ebert TJ, Hall JE, Barney JA et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382-394.

Aho M, Scheinin M, Lehtinen AM. Intramuscularly administered dexmedetomidine attenuates hemodynamic and stress hormone responses to gynecologic laparoscopy. Anesth Analg. 1992;75:932-939.

Fragen RJ, Fitzgerald PC. Effect of dexmedetomidine on the minimum alveolar concentration (MAC) of sevoflurane in adult age 55 to 70 years. J Clin Anesth. 1999;11:466-470.

Nociti JR, Serzedo PSM, Zuccolotto EB. Dexmedetomidina associada a propofol em sedação durante anestesia local para cirurgia plástica. Rev Bras Anestesiol. 2003;53:198-208.

Aho M, Lehtnen AM, Erkola O. The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane requirements in patients undergoing abdominal hysterectomy. Anesthesiology. 1991;74:997-1002.

Curtis FG, Castiglia YMM, Stolf AA. Dexmedetomidina e sufentanil como analgésicos per-operatórios: Estudo comparativo. Rev Bras Anestesiol. 2002;52:525-534.

Talke P, Chen R, Thomas B. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg. 2000;90:834-839.

Venn RM, Bradshaw CJ, Spencer R. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999;54:1136-1142.

Aantaa R, Kallio A, Virtanen R. Dexmedetomidine, a novel alpha2-adrenergic agonist: A review of its pharmacodynamic characteristics. Drugs Future. 1993;18:49-56.

Villela NR, Nascimento Jr P. Uso de dexmedetomidina em Anestesiologia. Rev Bras Anestesiol. 2003;53:97-113.

Jones MEP, Maze M. Can we characterize the central nervous system action of alpha2-adrenergic agonists?. Br J Anaesth. 2001;86:1-3.

Massone F. Anestesiologia Veterinária. 1999.

Monk TG, Mueller M, White PF. Treatment of stress response during balanced anesthesia: Comparative effects of isoflurane, alfentanil and trimethaphan. Anesthesiology. 1992;76:39-45.

Vickery RG, Sheridon BC, Segal IS. Anesthetic and hemodynamic effects of the steroisomers of medetomidine, an alpha2-adrenergic agonist, in halothane-anesthetized dogs. Anesth Analg. 1988;67:611-615.

Flacke JW, Flacke WE, Bloor BC. Hemodynamic effects of dexmedetomidine, an alpha2-adrenergic agonist, in autonomically denervated dogs. J Cardiovasc Pharmacol. 1990;16:616-623.

Schmeling WT, Kampine JP, Roerig DL et al. The effects of stereoisomers of the alpha2-adrenergic agonist medetomidine on systemic and coronary hemodynamics in conscious dogs. Anesthesiology. 1991;75:499-511.

Bloor BC, Alper G, Frankland M. Nifedipine attenuates the acute hemodynamic changes that occur with intravenous dexmedetomidine in dogs. Anesth Analg. 1989;68:S32.

Dyck JB, Maze M, Haack C. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993;78:813-820.

Proctor LT, Schmeling WT, Roerig D et al. Oral dexmedetomidine attenuates hemodynamic responses during emergence from general anesthesia in chronically instrumented dogs. Anesthesiology. 1991;74:108-114.

Zornow MH. Ventilatory, hemodynamic and sedative effects of the alpha2-adrenergic agonist, dexmedetomidine. Neuropharmacology. 1991;30:1065-1071.

Oku S, Benson KT, Hirakawa M. Renal sympathetic nerve activity after dexmedetomidine in nerve-intact and baroreceptor-denervated rabbits. Anesth Analg. 1996;83:477-481.

Mroczek WJ, Davidov M, Finnerty FA. Intravenous clonidine in hypertensive patients. Clin Pharmacol Ther. 1973;14:847-851.

Reis DJ, Morrison S, Ruggiero DA. The C1 area of the brainstem in tonic and reflex control of the circulation. Hypertension. 1988;11:8-13.

Svennson TH, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res. 1975;92:291-306.

Engelhard K, Werner C, Kaspar S. Effects of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology. 2002;96:450-457.

Ebert TJ, Hall JE, Barney JA. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382-394.

Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J Pharmacol. 1998;361:1-15.

Saunders C, Limbird LE. Localization and trafficking of alpha2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther. 1999;84:193-205.

Khan ZP, Furgson CN, Jones RM. Alpha-2 and imidazoline receptor agonists: Their pharmacology and therapeutic role. Anesthesia. 1999;54:146-165.

Kuusela E, Raekallio M, Anttila M. Clinical effects and pharmacokinetics of medetomidine and enantiomers in dogs. J Vet Pharmacol Therap. 2000;23:15-20.

Lawrence CJ, Prinzen FW, de Lange S. Comparison of the haemodynamic effects of the alpha-2 agonists clonidine and dexmedetomidine in the anaesthetized dog. J Cardiothorac Vasc Anesth. 1994;8:32.

Larach DR, Schuler HG, Derr JA. Halothane selectively attenuates alpha2-adrenoceptor mediated vasoconstriction, in vivo and in vitro. Anesthesiology. 1987;66:781-792.

Stevens WC, Cromwell TH, Hasey MJ. The cardiovascular effects of a new inhalation anesthetic, forane, in human volunteers at constant arterial carbon dioxide tension. Anesthesiology. 1971;35:8-16.

5ddc3eda0e8825e61bf2c91f rba Articles
Links & Downloads
2352-2291 (Electronic) 0104-0014 (Printed)
Braz J Anesthesiol ©2024 All rights reserved.

Braz J Anesthesiol

Share this page
Page Sections